Physician
Guillen, Tiu & Associates MD PA
Guillen, Tiu & Associates MD PA was paid $6.18M by Medicaid between Jan 2018 and Dec 2024, across 51 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoGUILLEN, TIU & ASSOCIATES MD PA
EDINBURG, TX 78539
EDINBURG, TX 78539
33aNPI1821005950assigned 08/02/2006
33bProvider typePediatrics Physician
28Total paid$6.18M
24GClaims233,715
24DCodes billed51
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#64 of 1,136
Median peer was paid$329K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 148 | $5K | |
| 2019 | 118 | $5K | |
| 2020 | 5,333 | $101K | |
| 2021 | 50,294 | $1.34M | |
| 2022 | 64,378 | $1.78M | |
| 2023 | 62,534 | $1.73M | |
| 2024incomplete | 50,910 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 56,695 | 47,563 | $2.08M |
| 86328 | 19% | 13,665 | 12,480 | $1.17M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 9.8% | 12,145 | 11,457 | $608K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.7% | 26,341 | 24,225 | $353K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.3% | 18,896 | 11,645 | $324K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.2% | 4,132 | 4,077 | $322K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.0% | 3,965 | 3,931 | $311K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.3% | 3,515 | 3,438 | $262K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.0% | 5,114 | 4,446 | $183K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.4% | 13,796 | 6,059 | $147K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 22,839 | 20,583 | $144K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.9% | 1,634 | 1,594 | $116K |
39 more codes
| 97802 | <1% | 19,607 | $43K | |
| 87807 | <1% | 2,979 | $31K | |
| 90461 | <1% | 3,880 | $16K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 561 | $13K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,549 | $12K |
| 99051 | <1% | 2,978 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 446 | $5K |
| 92551 | <1% | 2,500 | $5K | |
| 96160 | <1% | 2,107 | $4K | |
| 81002 | <1% | 611 | $2K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,732 | $2K |
| 83655 | <1% | 117 | $1K | |
| 90671 | <1% | 411 | $1K | |
| 99381 | <1% | 12 | $993.84 | |
| 90651 | <1% | 343 | $780.00 | |
| 97169 | <1% | 44 | $750.00 | |
| 90688 | <1% | 605 | $713.85 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $615.60 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 50 | $575.50 |
| 90620 | <1% | 87 | $200.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 50 | $105.60 |
| 96161 | <1% | 31 | $30.36 | |
| 90697 | 0% | 199 | $0.00 | |
| 90696 | 0% | 36 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 404 | $0.00 |
| 36416 | 0% | 3,322 | $0.00 | |
| 90680 | 0% | 334 | $0.00 | |
| 90723 | 0% | 112 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 17 | $0.00 |
| 99173 | 0% | 3,297 | $0.00 | |
| 90700 | 0% | 32 | $0.00 | |
| 90670 | 0% | 820 | $0.00 | |
| 90658 | 0% | 348 | $0.00 | |
| 90710 | 0% | 228 | $0.00 | |
| 90734 | 0% | 334 | $0.00 | |
| 90633 | 0% | 216 | $0.00 | |
| 90648 | 0% | 463 | $0.00 | |
| 90715 | 0% | 90 | $0.00 | |
| 90687 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALVAREZ, CYNTHIA (MANAGER)